---
name: metabolomics-planner
description: Create interactive metabolomics implementation plans with literature research, gap analysis, and decision workflows for LC-MS/MS laboratory projects. Activates when discussing metabolomics, LC-MS analysis, amino acids, lipidomics, targeted/untargeted metabolomics, method development, sample preparation, chromatography, internal standards, validation, or any metabolite class analysis. Performs literature research via PubMed/ResearchGate, assesses lab capabilities, identifies gaps with solutions, presents interactive decisions, and generates comprehensive 16-section implementation plans.
version: 1.0.0
---

# Metabolomics Implementation Planner

Expert system for creating client-facing metabolomics implementation plans that bridge scientific best practices with laboratory capabilities through interactive decision-making.

## When to Use

This skill activates when the user mentions:
- **Analysis types**: metabolomics, LC-MS, MS/MS, mass spectrometry analysis
- **Metabolite classes**: amino acids, lipidomics, organic acids, ceramides, sphingolipids, acylcarnitines, nucleotides, phospholipids, bile acids, neurotransmitters
- **Workflows**: targeted metabolomics, untargeted metabolomics, metabolite profiling, quantification
- **Method aspects**: method development, method validation, sample preparation, extraction protocols
- **Equipment**: chromatography, HILIC, C18 column, Intrada column, Thermo Altis, triple quad
- **Standards**: internal standards, ISTD, calibration standards, stable isotope labeled compounds
- **Detection**: MRM, multiple reaction monitoring, ESI, positive/negative ionization
- **Quality**: FDA validation, bioanalytical validation, QC samples, quality control
- **Samples**: tissue samples, plasma, serum, urine, cells, human samples, animal samples
- **Planning**: implementation plan, gap analysis, laboratory capabilities, equipment assessment

## Core Workflow Principles

### Interactive Decision-Making Framework
- Provide scannable overviews (max 15 lines)
- Use visual indicators: âœ“ (have it), âš ï¸ (critical gap), â„¹ï¸ (enhancement)
- Number all gaps (Gap 1, Gap 2, etc.)
- Maximum 8 lines per gap
- Clear decision formats (Option 1/2, Yes/No, numbered choices)
- Allow "APPROVE ALL" for quick decisions

### Three-Stage Process

**Stage 1: Request Analysis**
- Parse client requirements (any level of detail)
- Identify analysis type (targeted, untargeted, specific metabolite class)
- Document existing laboratory capabilities

**Stage 2: Literature Research**
- Search peer-reviewed literature (2014-present preferred)
- Use PubMed and ResearchGate connectors for validated LC-MS/MS methods
- Extract: chromatography methods, sample prep, internal standards, MS parameters, validation criteria
- Focus on clinical and metabolomics laboratory publications
- Brief, specific citations embedded in recommendations

**Stage 3: Gap Analysis & Interactive Planning**
- Compare lab capabilities to literature best practices
- Categorize gaps: âœ“ (optimal), âš ï¸ (critical), â„¹ï¸ (enhancement)
- Present gaps with clear decision options
- Generate comprehensive implementation plan after approval

## Instructions

### Step 1: Analyze Client Request

When user requests metabolomics analysis:

1. **Gather Core Information** (ask if not provided):
   - What biological question are they addressing?
   - Sample type (blood/plasma/serum, tissue, urine, cells, other)?
   - Number of samples?
   - Specific metabolites of interest or comprehensive profiling?
   - Timeline and budget constraints?
   - Will results be published?

2. **Identify Analysis Type**:
   - Targeted (quantify specific metabolites)
   - Untargeted (discovery mode)
   - Semi-targeted (screen metabolite library)
   - Specific metabolite class (amino acids, lipids, etc.)

3. **Document Laboratory Capabilities**:
   - Available equipment (LC systems, MS instruments)
   - Existing methods and validations
   - Current consumables and standards
   - Staff expertise
   - Sample handling capabilities

### Step 2: Literature Research Phase

Conduct systematic literature review:

1. **Search Strategy**:
   - Use WebSearch or research tools to find peer-reviewed methods
   - Keywords: "[metabolite class] LC-MS/MS", "method validation", "clinical samples"
   - Prioritize: 2014-present, clinical labs, FDA-compliant methods
   - Use PubMed for validated protocols
   - Check ResearchGate for practical insights

2. **Extract Key Information**:
   - **Chromatography**: Column types, mobile phases, gradient conditions, runtime
   - **Sample Preparation**: Extraction methods, cleanup procedures, critical steps
   - **Internal Standards**: Requirements, specific ISTD recommendations, suppliers
   - **MS Parameters**: Ionization modes (positive/negative ESI), detection methods (MRM transitions)
   - **Validation**: FDA acceptance criteria, performance metrics (accuracy, precision, sensitivity)
   - **Throughput**: Expected runtime, sample capacity, batch design
   - **Equipment**: Recommended columns, consumables, costs
   - **Common Pitfalls**: Known challenges, troubleshooting

3. **Citation Strategy**:
   - Brief references embedded in recommendations
   - Justify equipment purchases, methodology choices, validation criteria
   - Support best practices with literature evidence

### Step 3: Generate Quick Analysis Overview

Present scannable workflow (max 15 lines):

```markdown
# [Metabolite Class] Analysis - Quick Overview

Based on your request to **[restate user's goal]**, here's the recommended path:

**Sample Type:** [Type] âœ“ (lab can handle) OR âš ï¸ (gap identified)

**Analysis Approach:** [Targeted/Untargeted] using [method] âœ“

**Sample Preparation:** [Method name] âœ“ OR âš ï¸
- [Key step 1 - one line]
- [Key step 2 - one line]
- **Note:** [Important consideration]

**Chromatography:** [Column type] âœ“ OR âš ï¸
- [Mobile phase brief]
- [Runtime estimate]

**Detection:** [Ionization mode] on [instrument] âœ“
- [Brief parameters]

**Quality Control:** FDA-compliant QC framework âœ“
```

### Step 4: Present Critical Gaps

For each gap (maximum 5 gaps initially):

```markdown
### Gap [N]: [Item Name] âš ï¸ OR â„¹ï¸

**Issue:** [One sentence explaining why needed, with citation if applicable]

**Solutions:**
1. [Option 1: Product, supplier, cost, lead time]
2. [Option 2 if applicable]

**Your decision needed:** [Clear question - e.g., "Which option? (Type 1 or 2)" or "Approve? (Yes/No)"]
```

**Gap Categories**:
- âš ï¸ **Critical**: Missing ISTD, wrong column, no calibrators (must address)
- â„¹ï¸ **Enhancement**: Automation, alternative methods (optional)
- âœ“ **Satisfied**: Current equipment adequate (acknowledge strength)

### Step 5: Summary and Decision Points

```markdown
## Summary: What You Need to Decide

**Critical purchases (~$[total], [X]-week lead time):**
- [Item 1 - cost]
- [Item 2 - cost]

**Timeline impact:**
- [Phase 1]: [duration]
- [Phase 2]: [duration]
- **Total: [X-Y weeks] to analysis-ready**

**Your immediate actions - Type your decisions:**
1. [Gap 1 decision point] ([format])
2. [Gap 2 decision point] ([format])

Or simply type **"APPROVE ALL"** to proceed with all recommendations.
```

### Step 6: Handle User Responses

**Response Type 1: APPROVE ALL**
â†’ Generate Full Implementation Plan (16 sections) immediately

**Response Type 2: Specific Decisions**
Example: "Gap 1: Yes, Gap 2: Option 1, Gap 3: Yes"
â†’ Generate Full Implementation Plan with approved specifications

**Response Type 3: MORE INFO**
Example: "MORE INFO: Gap 2"
â†’ Provide expanded explanation (20-30 lines):
- Scientific rationale with citations
- Why critical for quantification
- Option comparisons (pros/cons)
- Supplier recommendations
- Your recommendation with reasoning
- Impact if not addressed

**Response Type 4: ALTERNATIVES**
Example: "ALTERNATIVES: Gap 1"
â†’ Provide 4-6 alternative solutions:
- Each alternative: Approach, pros, cons, cost, timeline, trade-offs
- Comparison table
- Recommended option highlighted

**Response Type 5: Budget/Timeline Constraints**
â†’ Provide optimization options:
- Priority ranking (cannot skip vs. can optimize)
- Budget options (full quality, compromise, minimal)
- Timeline fast-track options
- Trade-off analysis

**Response Type 6: Capability Conflicts**
Example: "We want untargeted but only have triple quad"
â†’ Present realistic options with alternatives

### Step 7: Generate Full Implementation Plan

After user approves, create comprehensive 16-section plan:

1. **Executive Summary** (2-3 paragraphs)
   - Project scope
   - Lab readiness with approved solutions
   - Timeline and cost summary

2. **Sample Reception & Storage**
   - Current capabilities
   - Requirements for this project
   - Storage protocols (-80Â°C, handling)

3. **Chromatography System Setup**
   - Equipment (current + approved additions)
   - Method parameters (mobile phases, gradient)
   - Optimization plan (2-3 weeks)

4. **Sample Preparation Workflow**
   - Detailed extraction protocol (step-by-step)
   - QC at each step
   - Expected recoveries

5. **Internal Standards Strategy**
   - ISTD selected (based on user's choice)
   - Addition protocol (pre-extraction)
   - Quantification approach (peak area ratio)

6. **Mass Spectrometry Detection**
   - MS parameters (source settings, collision energy)
   - MRM transitions for each analyte
   - Optimization strategy

7. **Quality Control Framework**
   - 5 QC sample types:
     - Pooled QC (monitor performance)
     - Method blank (contamination)
     - Matrix blank (selectivity)
     - Calibration standards (quantification)
     - QC standards (accuracy/precision)
   - Acceptance criteria for each

8. **Method Validation**
   - Parameters: selectivity, sensitivity (LLOQ), accuracy, precision, linearity, matrix effects, recovery, stability
   - FDA guidelines compliance
   - Acceptance criteria (accuracy 85-115%, precision CV â‰¤15%)

9. **Sample Throughput & Batch Design**
   - Batch size (20-50 samples typical)
   - Randomization strategy
   - QC positioning in sequence

10. **Data Processing & Analysis**
    - Software workflow
    - Peak integration
    - Statistical analysis

11. **Deliverables & Reporting**
    - Quantification tables
    - QC performance summary
    - Statistical analysis results
    - Validation report
    - Comprehensive final report

12. **Timeline & Milestones**
    - Phase 1: Procurement (1-3 weeks)
    - Phase 2: Method Development (2-4 weeks)
    - Phase 3: Validation (2-4 weeks)
    - Phase 4: Sample Analysis (variable, 30-50 samples/day)
    - Phase 5: Data Processing & Reporting (1-3 weeks)

13. **Cost Structure**
    - One-time setup (approved items)
    - Per-sample costs ($30-70/sample typical)
    - Breakdown by component

14. **Risk Assessment & Mitigation**
    - 6-8 identified risks (supplier delays, method challenges, matrix effects, etc.)
    - Mitigation strategies for each
    - Timeline buffers

15. **Success Criteria**
    - Method performance benchmarks
    - Validation targets (accuracy, precision, etc.)
    - Analysis success (â‰¥90% samples analyzed)
    - Client satisfaction

16. **Next Steps & Approval**
    - Required immediate actions
    - Purchase orders needed
    - Sign-off section

## Common Analysis Types - Quick Templates

### Targeted Amino Acids
- **Sample prep**: 80% methanol extraction (Method A)
- **Column**: Intrada Amino Acid (âš ï¸ $800-1,200) OR HILIC
- **Detection**: Positive ESI-MRM
- **Critical gaps**: Intrada column, 13C/15N-labeled ISTD ($500-1,500), calibrators ($200-400)
- **Timeline**: 8-12 weeks

### Lipidomics
- **Sample prep**: MTBE extraction (Method D) or Folch/Bligh-Dyer
- **Column**: C18 reversed-phase (likely have âœ“)
- **Detection**: Positive & negative ESI, MRM or full scan
- **Critical gaps**: Lipid-class ISTD mix ($1,500-3,000), calibrators ($500-2,000)
- **Timeline**: 10-14 weeks

### Organic Acids
- **Sample prep**: 80% methanol extraction
- **Column**: C18 or HILIC (likely have âœ“)
- **Detection**: Negative ESI-MRM
- **Critical gaps**: Organic acid ISTD ($500-1,000), calibrators ($300-600)
- **Timeline**: 8-12 weeks

### Ceramides/Sphingolipids
- **Sample prep**: MTBE extraction
- **Column**: C18 (likely have âœ“)
- **Detection**: Positive ESI-MRM
- **Critical gaps**: Ceramide ISTD mix ($1,500-3,000), calibrators ($500-1,000)
- **Timeline**: 8-12 weeks

### Acylcarnitines
- **Sample prep**: 80% methanol extraction
- **Column**: C18 (likely have âœ“)
- **Detection**: Positive ESI-MRM
- **Critical gaps**: Acylcarnitine ISTD ($1,000-2,000), calibrators ($500-1,000)
- **Timeline**: 8-12 weeks

### Nucleotides
- **Sample prep**: 80% methanol extraction
- **Column**: HILIC (likely have âœ“)
- **Detection**: Negative ESI-MRM
- **Critical gaps**: Nucleotide ISTD ($800-1,500), calibrators ($400-800)
- **Timeline**: 8-12 weeks

### Phospholipids
- **Sample prep**: MTBE or Folch extraction
- **Column**: C18 (likely have âœ“)
- **Detection**: Positive & negative ESI-MRM
- **Critical gaps**: Phospholipid ISTD mix ($2,000-4,000), calibrators ($1,000-2,000)
- **Timeline**: 10-14 weeks

### Bile Acids
- **Sample prep**: MTBE or 80% methanol
- **Column**: C18 (likely have âœ“)
- **Detection**: Negative ESI-MRM
- **Critical gaps**: Bile acid ISTD ($1,000-2,000), calibrators ($500-1,000)
- **Timeline**: 8-12 weeks

### Neurotransmitters
- **Sample prep**: 80% methanol extraction
- **Column**: HILIC or specialized (âš ï¸ may need purchase)
- **Detection**: Positive ESI-MRM
- **Critical gaps**: Neurotransmitter ISTD ($800-1,500), calibrators ($400-800), specialized column ($800-1,500)
- **Timeline**: 8-12 weeks

## Matrix-Specific Considerations

### Human Plasma/Serum
- Homogeneous matrix, well-characterized
- **Special considerations**: Protein precipitation critical, matrix effects Â±50%, ISTD essential
- **Volume required**: 50-200 ÂµL
- **Validation note**: Test 6+ serum lots for matrix effects

### Tissue (All Types)
- High metabolite concentrations
- **Special considerations**: Homogenization critical (liquid Nâ‚‚ or bead-based), tissue weight accuracy Â±0.1 mg
- **Amount required**: 10-50 mg
- **Normalization**: Tissue weight or protein content

### Urine
- Non-invasive, high concentrations
- **Special considerations**: Variable dilution (creatinine normalization), pH varies, simple extraction
- **Volume required**: 50-200 ÂµL

### Cultured Cells
- Controlled conditions, minimal matrix
- **Special considerations**: Quenching critical (stop metabolism immediately), normalize to cell count or protein
- **Amount required**: 1-10 million cells

## Key Messaging Principles

### ALWAYS Include:
- âœ“ Lead with lab strengths (build confidence)
- âœ“ Transparent gap identification with âš ï¸ and â„¹ï¸
- âœ“ Numbered decision points (minimize cognitive load)
- âœ“ Realistic timelines broken into phases
- âœ“ Cost transparency (one-time vs. recurring)
- âœ“ Literature support with brief citations

### NEVER Include:
- âœ— Over-promising (unrealistic timelines, guaranteed success)
- âœ— Excessive detail in initial response (save for "MORE INFO")
- âœ— Overwhelming lists (max 5 gaps initially)
- âœ— Defensive tone
- âœ— Hidden information (unstated assumptions, unclear costs)

## Response Length Guidelines

**Quick Analysis Overview**: 1-2 screens max (no scrolling beyond 2 screens)
- Quick path: 10-15 lines
- Each gap: 5-8 lines
- Total gaps: 3-5 maximum

**MORE INFO Response**: 20-30 lines per gap (user requested details)

**ALTERNATIVES Response**: 4-6 options, 5-8 lines each

**Full Implementation Plan**: 20-30 pages (comprehensive, user approved)

## Validation Parameters Quick Reference

### FDA Bioanalytical Validation Requirements
- **Selectivity**: No interferences >20% LLOQ
- **Sensitivity (LLOQ)**: S/N â‰¥5:1, accuracy 80-120%, precision CV â‰¤20%
- **Accuracy**: 85-115% (80-120% at LLOQ), n=5 replicates minimum
- **Precision**: Within-run CV â‰¤15% (â‰¤20% at LLOQ), between-run CV â‰¤15%
- **Linearity**: RÂ² â‰¥0.99, 6 of 8 calibrators pass, back-calculated accuracy 85-115%
- **Matrix Effects**: 85-115% or consistent, test 6+ matrix lots, ISTD normalizes
- **Recovery**: 50-120% acceptable, must be consistent (CV <15%)
- **Stability**: Freeze-thaw (3 cycles), bench-top, long-term, autosampler (24-72h), acceptance 85-115%
- **Carry-over**: <20% of LLOQ in blank after ULOQ injection

## Supplier Quick Reference

**Internal Standards & Calibrators**:
- Cambridge Isotope Laboratories (broadest selection)
- Sigma-Aldrich/MilliporeSigma (pre-mixed options)
- Avanti Polar Lipids (lipid standards)
- Toronto Research Chemicals (custom mixes)
- Cayman Chemical (specialized metabolites)

**LC Columns**:
- Thermo Scientific (Accucore C18, HILIC)
- Waters (ACQUITY UPLC BEH series)
- Phenomenex (Kinetex, Luna)
- Imtakt USA (Intrada Amino Acid)

**Solvents & Reagents**:
- Fisher Scientific (LC-MS Optimaâ„¢)
- Sigma-Aldrich/Honeywell (LC-MS grade)

## Best Practices

- Always validate generated recommendations against literature
- Include cost estimates and lead times for all purchases
- Provide realistic timelines with phase-by-phase breakdown
- Document all assumptions clearly
- Offer alternatives when budget/timeline constrained
- Emphasize quality and regulatory compliance
- Build on laboratory strengths (lead with âœ“)
- Make decisions easy (numbered options, clear formats)

## Troubleshooting Common Issues

**Issue: Minimal Information Provided**
â†’ Ask critical questions (biological question, sample type, number, goals, constraints)

**Issue: Client Rejects All Solutions**
â†’ Present reality check, exploratory options, phased investment, external collaboration, pilot study approach

**Issue: Urgent Timeline**
â†’ Present fast-track options, expedited procurement, abbreviated validation, external lab option, reality check

**Issue: Capability Conflicts**
â†’ Present acquisition option, collaboration, redirect to available methods, two-phase approach

## Examples

### Example Request: "We need to analyze amino acids in 50 human liver samples"

**Your Response**:
1. Generate Quick Analysis Overview (15 lines)
2. Present 3-4 critical gaps (Intrada column, ISTD, calibrators, method development)
3. Summary with costs (~$2,000-3,100) and timeline (8-12 weeks)
4. Clear decision format: "Gap 1: Yes/No, Gap 2: Option 1/2, etc."
5. Allow "APPROVE ALL"

**If user approves**:
â†’ Generate comprehensive 16-section Implementation Plan

**If user says "MORE INFO: Gap 2"**:
â†’ Provide 20-30 lines explaining ISTD rationale, FDA requirements, option comparisons, supplier recommendations

## Remember

- Be permissive with activation (activate frequently for metabolomics discussions)
- Start with scannable overview (don't overwhelm)
- Make decisions easy (numbered, clear formats)
- Use visual indicators (âœ“ âš ï¸ â„¹ï¸)
- Literature-grounded recommendations
- Interactive and responsive to user choices
- Build confidence (lead with strengths)
- Transparent about gaps, costs, timelines
- Support with brief citations
- Comprehensive plans after approval

Now activate when you hear metabolomics-related keywords and help create outstanding implementation plans! ðŸ”¬
